Clinical Trial Update: IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating salvage treatment with IBER followed by Ibrutinib maintenance for relapsed or refractory primary central nervous system lymphoma (PCNSL…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• IBER
• Ibrutinib (ibrutinib)

Snippet

Sponsor: Deok-Hwan Yang | Conditions: Primary Central Nervous System Lymphoma | Phase 2 | Status: UNKNOWN